What is RVMD's current stock price?

Revolution Medicines, Inc. (RVMD) is currently trading at $98.97 per share.

What is the analyst price target for RVMD?

Analyst price target information is not currently available for RVMD.

What sector is Revolution Medicines, Inc. in?

Revolution Medicines, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RVMD's market cap?

Market capitalization information is not currently available for RVMD.

Does RVMD pay dividends?

No, Revolution Medicines, Inc. does not currently pay a dividend to shareholders.

Revolution Medicines, Inc. (RVMD) Stock Price & AI Analysis

GoAI Score

Sign in to unlock

Valuation

50Fair Value

Sentiment

100Bullish

Risk

80Low Risk

Momentum

75Positive

Institutional-Grade Intelligence

🏆PRO

Actionable Intelligence

AI-driven stance, execution logic & risk thresholds

Catalyst Roadmap

Event timeline with expected impact & market context

Deep Insights

Fact-checked analysis & score logic breakdown

Financial Statements

Margin Trends

Gross

—

Revenue after COGS

Operating

—

After operating expenses

Net

—

Bottom-line profitability

Gross Margin

Operating Margin

Net Margin

Valuation Snapshot

P/E Ratio

-13.4

Price vs earnings

EV/EBITDA

-13.7

Enterprise value

FCF Yield

-6.0%

Cash generation

Earnings Yield

-7.5%

Inverse of P/E

Capital Efficiency

-59

GoAI Quality ScorePoor

ROEReturn on Equity

-69.3%Weak

ROAReturn on Assets

-48.0%Weak

ROICReturn on Invested Capital

-56.8%Weak

Financial Health

Current RatioHealthy

7.14

Short-term solvency (>1.5)

Net Debt / EBITDAManageable

0.21x

Debt repayment capacity (<3x)

Income QualityFair

0.79

Cash backs earnings (>1)

Revenue & Profitability

Revenue

Net Income

Net Loss

Income Statement

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	$11.58M	$35.38M	$29.39M
Gross Profit	-$16.56M	N/A	$11.58M	$35.38M	$29.39M
Gross Margin	N/A	N/A	100.0%	100.0%	100.0%
Operating Income	-$1.18B	-$689.52M	-$487.19M	-$258.28M	-$188.01M
Net Income	-$1.13B	-$600.09M	-$436.37M	-$248.71M	-$187.09M
Net Margin	N/A	N/A	-3768.3%	-703.0%	-636.6%
EPS	-$5.95	-$3.58	-$3.86	-$3.08	-$2.47

Average Price Target

$124.36▲ 25.7% Upside

Past 12 Months

12 Month Forecast

Based on 50 Wall Street analysts offering 12 month price targets for Revolution Medicines, Inc., the average price target is $124.36, with a high forecast of $170.00 and a low forecast of $73.00. The average price target represents a 25.7% increase from the current price of $98.97.

Highest

$170.00

Average

$124.36

Lowest

$73.00

Rating Distribution

Strong Buy

1

5%

Buy

18

90%

Hold

1

5%

Sell

0

0%

Strong Sell

0

0%

Recent Analyst Ratings

FirmActionRatingDate

Wells Fargo● Maintain

Overweight

2026-02-26

Needham● Maintain

Buy

2026-02-26

Piper Sandler● Maintain

Overweight

2026-02-26

JP Morgan● Maintain

Overweight

2026-02-02

Oppenheimer● Maintain

Outperform

2026-01-27

Stifel● Maintain

Buy

2026-01-22

RBC Capital● Maintain

Outperform

2026-01-21

Guggenheim● Maintain

Buy

2026-01-20

Mizuho● Maintain

Outperform

2026-01-13

Wedbush● Maintain

Outperform

2025-11-06

Earnings History & Surprises

BEAT RATE

33%

Last 18 quarters

AVG SURPRISE

-5.7%

EPS vs Estimate

BEATS / MISSES

6/11

1 met exactly

LATEST EPS

$-1.86

Q1 '26

QUARTERLY EPS TREND

Estimated

Beat

Miss

QUARTERLY DETAIL

Q1 '26

-17.6%

$-1.86 vs $-1.58

Q4 '25

-13.4%

$-1.61 vs $-1.42

Q3 '25

-39.4%

$-1.31 vs $-0.94

Q2 '25

-0.9%

$-1.13 vs $-1.12

Q1 '25

-10.9%

$-1.12 vs $-1.01

Q4 '24

-5.2%

$-0.94 vs $-0.89

Q3 '24

-5.2%

$-0.81 vs $-0.77

Q2 '24

+6.2%

$-0.70 vs $-0.75

Q1 '24

-32.6%

$-1.14 vs $-0.86

Q4 '23

+2.0%

$-0.99 vs $-1.01

Q3 '23

-10.8%

$-0.92 vs $-0.83

Q2 '23

+14.3%

$-0.72 vs $-0.84

No investor questions available.

Latest News

No news available